References
1. Wataya-Kaneda M, Nagai H, Ohno Y, et al. Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial. Dermatol Ther (Heidelb). 2020;10(4):635-650. doi:10.1007/s13555-020-00387-7.
2. Sadowski K, Kotulska K, Schwartz RA, Jóźwiak S. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review. J Eur Acad Dermatol Venereol. 2016;30(4):586-594. doi:10.1111/jdv.13356
3. Kennedy RA, Thavaraj S, Diaz-Cano S. An Overview of Autosomal Dominant Tumour Syndromes with Prominent Features in the Oral and Maxillofacial Region. Head Neck Pathol. 2017;11(3):364-376. doi:10.1007/s12105-017-0778-1
4. Lujber L, Burián A. Giant nasal mass causing feeding difficulty in tuberous sclerosis. Otolaryngol Head Neck Surg. 2011;145(3):511-512. doi:10.1177/0194599811410280.
5. Earnest L, Byrne P, Califano J. Massive facial angiofibroma in a patient with tuberous sclerosis. Otolaryngol Head Neck Surg. 2003;128(1):151-153. doi:10.1067/mhn.2003.49
Figure 1 Multiple 2-4 mm facial angiofibromas around the nose.
Figure 2 Total obstruciton of MAE due to angiofibromas.
Figure 3 MAE patency and adapted preauricular fasciocutaneous island flap.